{"id":"bifeprunox-olanzapine","safety":{"commonSideEffects":[{"rate":"null","effect":"Weight gain"},{"rate":"null","effect":"Dyslipidemia"},{"rate":"null","effect":"Hyperprolactinemia"},{"rate":"null","effect":"Somnolence"},{"rate":"null","effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bifeprunox and olanzapine work by blocking the action of dopamine and serotonin in the brain, which helps to reduce symptoms of schizophrenia and bipolar disorder. Bifeprunox has a more selective mechanism of action compared to olanzapine, with a higher affinity for the dopamine D2 receptor. This may contribute to its potential therapeutic benefits and reduced side effects.","oneSentence":"Bifeprunox is a selective dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist, and olanzapine is a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:16.580Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder"}]},"trialDetails":[{"nctId":"NCT00193713","phase":"PHASE3","title":"Bifeprunox in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2005-05","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00230828","phase":"PHASE3","title":"Patient-reported Outcomes in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2005-05","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00347425","phase":"PHASE3","title":"Switch Study of Existing Atypical Antipsychotics to Bifeprunox","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2006-12","conditions":"Schizophrenia and Schizoaffective Disorder","enrollment":286},{"nctId":"NCT00380224","phase":"PHASE3","title":"Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-07","conditions":"Schizophrenia","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"bifeprunox, olanzapine","genericName":"bifeprunox, olanzapine","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bifeprunox is a selective dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist, and olanzapine is a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. Used for Schizophrenia, Bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}